Company intelligence / Profile preview
Multitude Therapeutics
Redwood City, California, United Statesmultitudetherapeutics.info ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Multitude Therapeutics has advanced several first-in-class and best-in-class ADCs into the clinic, demonstrating good safety and efficacy in early-stage trials. Their proprietary platforms have enabled the identification of novel cancer targets and development of differentiated ADC candidates, with preliminary clinical validation supporting their approach.[5][1]
- Therapeutic areas
- OncologyHematology
- Modalities
- Antibody-drug conjugates (ADCs)Bispecific antibodiesCAR-T cell therapies[3]
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
Adcendo ApS – global licensing agreement for TF-targeting ADC asset ADCE-T02; Adcendo holds ex-Greater China rights, Multitude retains Greater China rights.[5]WuXi XDC – strategic partnership for co-development of proprietary T-Moiety linker technologies for bioconjugates/ADCs.[4]
Beyond the preview
Go deeper on Multitude Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Multitude Therapeutics.